Arcutis Biotherapeutics, INC Form 4 insider transactions

Arcutis Biotherapeutics' CFO, Latha Vairavan, reported the acquisition of restricted stock units and stock options, alongside sales to cover tax obligations.

Arcutis Biotherapeutics' EVP, Chief Medical Officer Patrick Burnett, reported acquisitions of common stock via RSU vesting and stock option grants, alongside sales to cover tax obligations.

Arcutis Biotherapeutics' SVP General Counsel and Corporate Secretary, Masaru Matsuda, reported the sale of 40,638 common shares, primarily to cover tax obligations and under a 10b5-1 trading plan.

Arcutis Biotherapeutics' EVP and Chief Medical Officer, Patrick Burnett, sold shares of common stock in early February 2026, primarily to cover tax obligations related to RSU vesting and under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics CEO Todd Watanabe sold 19,833 shares of common stock on February 2, 2026, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Arcutis Biotherapeutics' SVP Chief Financial Officer, Latha Vairavan, sold 1,320 shares of common stock on February 2, 2026, to cover tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for approximately $25.05 per share under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics' EVP Chief Commercial Officer, Larry Todd Edwards, sold 2,052 shares of common stock to cover tax withholding obligations related to RSU vesting.

Patrick Burnett, Arcutis Biotherapeutics' EVP and Chief Medical Officer, sold 2,490 shares of common stock at a weighted average price of $28.98 per share through a pre-scheduled 10b5-1 trading plan.

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for approximately $28.96 per share, executed under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 1,697 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, exercised stock options and subsequently sold 11,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics director Amit Munshi received 2,021 Restricted Stock Units and options for 22,679 shares as part of his compensation.

Arcutis Biotherapeutics' SVP General Counsel, Masaru Matsuda, sold 1,657 shares of common stock at $30.23 per share under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for a weighted average price of $30.2133 per share, executed under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics Director Sue-Jean Lin exercised stock options and subsequently sold a portion of the acquired common stock on November 24, 2025.

Arcutis Biotherapeutics President and CEO Todd Watanabe sold common stock totaling 50,000 shares in November 2025 under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics' SVP General Counsel, Masaru Matsuda, sold shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

Halley E. Gilbert, a director at Arcutis Biotherapeutics, Inc., exercised stock options and subsequently sold a portion of common stock.

Arcutis Biotherapeutics Director Neha Krishnamohan exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics Director Keith R. Leonard reported gifting 4,312 shares of common stock to a Charitable Remainder Unitrust.

Arcutis Biotherapeutics' EVP Chief Commercial Officer, Larry Todd Edwards, reported the sale of 29,131 shares of common stock for approximately $25.16 per share.

Patrick Burnett, Arcutis Biotherapeutics' EVP and Chief Medical Officer, executed a pre-planned sale of 17,250 common shares after exercising stock options, realizing a significant gain.

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 6,486 shares of common stock to cover tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for approximately $25.27 per share under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics' SVP Chief Financial Officer, Latha Vairavan, sold 88 shares of common stock to cover tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics CEO Todd Watanabe sold 11,547 shares of common stock on November 3, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Arcutis Biotherapeutics' SVP General Counsel and Corporate Secretary, Masaru Matsuda, sold shares to cover tax obligations related to RSU vesting.

Arcutis Biotherapeutics CEO Todd Watanabe sold 40,000 shares of common stock for approximately $25.03 per share under a Rule 10b5-1 trading plan.

Arcutis Biotherapeutics' EVP Chief Commercial Officer, Larry Todd Edwards, sold 4,504 shares of common stock to cover tax withholding obligations related to RSU vesting.